<DOC>
	<DOC>NCT01959386</DOC>
	<brief_summary>This observational study will evaluate the efficacy, safety, tolerability and patient reported quality of life of Herceptin (trastuzumab) subcutaneous therapy in patients with HER2-positive early breast cancer in routine clinical practice. Data from eligible patients will be collected for the duration of their treatment (approximately 1 year) and for 1-2 years of follow-up.</brief_summary>
	<brief_title>HerSCin: An Observational Study of Herceptin (Trastuzumab) Subcutaneous in Patients With HER2-Positive Early Beast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Female or male adult patient; &gt;/= 18 years of age Histologically confirmed adenocarcinoma of the breast HER2positive tumor Eligible for neoadjuvant or adjuvant treatment with Herceptin SC according to the judgement of the physician Note: As of patient recruitment (date of patient informed consent), retrospective documentation is allowed but limited to up to 9 weeks after initial start of therapy with Herceptin SC Contraindications according to the Summary of Product Characteristics of Herceptin SC Pregnant and breastfeeding women</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>